Verastem Inc

Verastem, Inc. is a biopharmaceutical firm in its development phase, concentrating on the advancement and market introduction of therapeutic agents for oncological conditions. A primary investigational compound is VS-6766 (also known as avutometinib). This agent functions as a RAF/MEK clamp, impeding MEK kinase activity and the capacity of RAF to phosphorylate MEK. Its pipeline includes RAMP 201, an adaptive, two-part, multicenter, parallel cohort, randomized, open-label clinical trial. This study assesses the effectiveness and safety of avutometinib, both as a standalone treatment and in conjunction with defactinib, an oral small molecule inhibitor of focal adhesion kinase (FAK), for individuals with recurrent low-grade serous ovarian cancer. Furthermore, RAMP 202 is a Phase 2 investigation exploring the safety of VS-6766 when co-administered with defactinib in patients diagnosed with KRAS and BRAF mutant non-small cell lung cancer, particularly after they have undergone platinum-based therapy and immune checkpoint inhibition. The company holds significant licensing agreements: one with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and production of products containing avutometinib, and another with Pfizer Inc. granting rights to research, develop, manufacture, and commercialize therapeutic, diagnostic, and prophylactic human applications utilizing Pfizer's FAK inhibitors. Verastem has also forged strategic collaborations. A clinical partnership with Amgen, Inc. involves the RAMP 203 Phase 1/2 trial, which is evaluating avutometinib in combination with Amgen's KRAS-G12C inhibitor, LUMAKRASTM. Additionally, a discovery and development partnership with GenFleet Therapeutics is focused on advancing novel programs aimed at cancers driven by the RAS pathway. Verastem, Inc., founded in 2010, has its corporate headquarters situated in Needham, Massachusetts.